WILMINGTON– NeuroRx, a Wilmington clinical stage biopharma company developing the first drug regimen to treat severe bipolar depression, has retained J.P. Morgan as financial advisor.
NeuroRx will begin enrolling patients shortly in a Phase 2b/3 pivotal study targeting severe bipolar depression in patients with acute suicidal ideation and behavior. The FDA awarded fast track designation to the drug regimen in August.
The FDA awarded FAST TRACK designation to this investigational drug regimen in August, 2017.
There currently is no approved drug therapy for bipolar depression in patients with acute suicidal ideation and behavior. The only FDA-approved treatment is electroconvulsive therapy.